Advances in molecular-specific optical contrast agents have recently shown promise for the detection of cancer and its precursors. Targeting agents that have been successfully used for optical detection of cancer biomarkers in preclinical models include antibodies,
1, 2, 3, 4, 5, 6 growth factors,
7, 8, 9, 10, 11 peptide analogs of extracellular ligands,
12, 13, 14, 15 and enzymatically activatable polymers.
16, 17, 18, 19, 20 The coupling of optical tags to these targeting agents allows molecular events to be monitored noninvasively
in vivo.
21 These molecular-specific optical contrast agents have the potential to provide dynamic, real-time information without the need for biopsy and associated patient discomfort.